Impact of COVID-19 and Non-COVID-19 Vaccination in Special Populations
Vaccination is crucial for reducing morbidity and mortality; however, vaccine hesitancy poses a significant challenge, often driven by a lack of confidence in vaccine safety and efficacy. The World Health Organization defines vaccine hesitancy as the delay in acceptance or refusal of vaccines despit...
में बचाया:
| स्वरूप: | Online |
|---|---|
| भाषा: | अंग्रेज़ी |
| प्रकाशित: |
MDPI - Multidisciplinary Digital Publishing Institute
2025
|
| विषय: | |
| ऑनलाइन पहुंच: | ONIX_20250220_9783725826469_372 |
| टैग: |
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|
| _version_ | 1869529770675404800 |
|---|---|
| collection | Directory of Open Access Books |
| description | Vaccination is crucial for reducing morbidity and mortality; however, vaccine hesitancy poses a significant challenge, often driven by a lack of confidence in vaccine safety and efficacy. The World Health Organization defines vaccine hesitancy as the delay in acceptance or refusal of vaccines despite their availability. To enhance vaccination uptake, it is vital to provide evidence demonstrating vaccine safety and efficacy, especially for populations prone to hesitancy. This Special Issue focuses on four specific groups: children, older adults, patients with comorbid conditions, and risk-averse individuals. Research highlighted in this issue reveals that the COVID-19 vaccines generally have high efficacy and low serious adverse event rates in children. Older adults often lack adequate vaccination guidelines tailored to their specific health needs, stressing the necessity for more comprehensive recommendations. Additionally, patients with autoimmune diseases showed impaired immunity to vaccines, though a second dose proved beneficial without increasing adverse events. Moreover, risk-averse individuals demonstrated anxiety during vaccinations, particularly those with severe allergies, but this could be alleviated in controlled environments. Lastly, those with prior COVID-19 infections experienced “pandemic fatigue,” elevating their vaccine hesitancy. The findings underscore the need for targeted education and support to encourage vaccination across these diverse populations, ultimately preserving public health and preventing societal disruptions. |
| format | Online |
| id | doab-20.500.12854ir-153008 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2025 |
| publishDateRange | 2025 |
| publishDateSort | 2025 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1530082025-02-20T13:25:13Z Impact of COVID-19 and Non-COVID-19 Vaccination in Special Populations See, Kay Choong vaccine COVID-19 SARS-CoV-2 allergy anxiety COVID-19 vaccine children adverse reactions immunogenicity efficacy meta-analysis vaccines coronavirus infectious diseases adverse events COVID-19 vaccination relapsing multiple sclerosis ofatumumab neutralizing antibodies T-cell responses vaccination guidelines geriatric elderly public health review booster comorbidity antibody response healthcare worker adverse event mRNA vaccine inactivated viral vaccine autoimmune safety adolescent 12–17 years COVID-19 vaccine fully vaccinated partially vaccinated vaccination status RT-PCR-positive Pfizer BNT162b2 vaccine effectiveness pandemic fatigue vaccine hesitancy hearing loss hearing impairment deaf deafness n/a thema EDItEUR::A The Arts::AT Performing arts::ATD Theatre studies thema EDItEUR::A The Arts::AV Music Vaccination is crucial for reducing morbidity and mortality; however, vaccine hesitancy poses a significant challenge, often driven by a lack of confidence in vaccine safety and efficacy. The World Health Organization defines vaccine hesitancy as the delay in acceptance or refusal of vaccines despite their availability. To enhance vaccination uptake, it is vital to provide evidence demonstrating vaccine safety and efficacy, especially for populations prone to hesitancy. This Special Issue focuses on four specific groups: children, older adults, patients with comorbid conditions, and risk-averse individuals. Research highlighted in this issue reveals that the COVID-19 vaccines generally have high efficacy and low serious adverse event rates in children. Older adults often lack adequate vaccination guidelines tailored to their specific health needs, stressing the necessity for more comprehensive recommendations. Additionally, patients with autoimmune diseases showed impaired immunity to vaccines, though a second dose proved beneficial without increasing adverse events. Moreover, risk-averse individuals demonstrated anxiety during vaccinations, particularly those with severe allergies, but this could be alleviated in controlled environments. Lastly, those with prior COVID-19 infections experienced “pandemic fatigue,” elevating their vaccine hesitancy. The findings underscore the need for targeted education and support to encourage vaccination across these diverse populations, ultimately preserving public health and preventing societal disruptions. 2025-02-20T13:25:11Z 2025-02-20T13:25:11Z 2024 book ONIX_20250220_9783725826469_372 9783725826469 9783725826452 https://directory.doabooks.org/handle/20.500.12854/153008 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/10223 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-2645-2 10.3390/books978-3-7258-2645-2 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725826469 9783725826452 158 Basel open access |
| spellingShingle | vaccine COVID-19 SARS-CoV-2 allergy anxiety COVID-19 vaccine children adverse reactions immunogenicity efficacy meta-analysis vaccines coronavirus infectious diseases adverse events COVID-19 vaccination relapsing multiple sclerosis ofatumumab neutralizing antibodies T-cell responses vaccination guidelines geriatric elderly public health review booster comorbidity antibody response healthcare worker adverse event mRNA vaccine inactivated viral vaccine autoimmune safety adolescent 12–17 years COVID-19 vaccine fully vaccinated partially vaccinated vaccination status RT-PCR-positive Pfizer BNT162b2 vaccine effectiveness pandemic fatigue vaccine hesitancy hearing loss hearing impairment deaf deafness n/a thema EDItEUR::A The Arts::AT Performing arts::ATD Theatre studies thema EDItEUR::A The Arts::AV Music Impact of COVID-19 and Non-COVID-19 Vaccination in Special Populations |
| title | Impact of COVID-19 and Non-COVID-19 Vaccination in Special Populations |
| title_full | Impact of COVID-19 and Non-COVID-19 Vaccination in Special Populations |
| title_fullStr | Impact of COVID-19 and Non-COVID-19 Vaccination in Special Populations |
| title_full_unstemmed | Impact of COVID-19 and Non-COVID-19 Vaccination in Special Populations |
| title_short | Impact of COVID-19 and Non-COVID-19 Vaccination in Special Populations |
| title_sort | impact of covid 19 and non covid 19 vaccination in special populations |
| topic | vaccine COVID-19 SARS-CoV-2 allergy anxiety COVID-19 vaccine children adverse reactions immunogenicity efficacy meta-analysis vaccines coronavirus infectious diseases adverse events COVID-19 vaccination relapsing multiple sclerosis ofatumumab neutralizing antibodies T-cell responses vaccination guidelines geriatric elderly public health review booster comorbidity antibody response healthcare worker adverse event mRNA vaccine inactivated viral vaccine autoimmune safety adolescent 12–17 years COVID-19 vaccine fully vaccinated partially vaccinated vaccination status RT-PCR-positive Pfizer BNT162b2 vaccine effectiveness pandemic fatigue vaccine hesitancy hearing loss hearing impairment deaf deafness n/a thema EDItEUR::A The Arts::AT Performing arts::ATD Theatre studies thema EDItEUR::A The Arts::AV Music |
| topic_facet | vaccine COVID-19 SARS-CoV-2 allergy anxiety COVID-19 vaccine children adverse reactions immunogenicity efficacy meta-analysis vaccines coronavirus infectious diseases adverse events COVID-19 vaccination relapsing multiple sclerosis ofatumumab neutralizing antibodies T-cell responses vaccination guidelines geriatric elderly public health review booster comorbidity antibody response healthcare worker adverse event mRNA vaccine inactivated viral vaccine autoimmune safety adolescent 12–17 years COVID-19 vaccine fully vaccinated partially vaccinated vaccination status RT-PCR-positive Pfizer BNT162b2 vaccine effectiveness pandemic fatigue vaccine hesitancy hearing loss hearing impairment deaf deafness n/a thema EDItEUR::A The Arts::AT Performing arts::ATD Theatre studies thema EDItEUR::A The Arts::AV Music |
| url | ONIX_20250220_9783725826469_372 |